Antitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model

Stem Cells Translational Medicine

Volumn 3, Issue 8, 2014, Pages 923-935

  Purwanti, Yovita Ida ^a,b   Chen, Can ^a   Lam, Dang Hoang ^a,b   Wu, Chunxiao ^b   Zeng, Jieming ^b   Fan, Weimin ^c   Wang, Shu ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^c University College of Medicine   (China)

Author keywords

Cancer therapy; CD40 ligand; Endothelial progenitor cells; Human iPS cells

Indexed keywords

CASPASE 3; CASPASE 7; CD133 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE IMAGING; BREAST METASTASIS; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMAGING; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; LUNG METASTASIS; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; QUANTITATIVE ANALYSIS; TROPISM; TUMOR GROWTH; TUMOR TROPISM;

CANCER THERAPY; CD40 LIGAND; ENDOTHELIAL PROGENITOR CELLS; HUMAN IPS CELLS;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD34; BACULOVIRIDAE; BREAST NEOPLASMS; CD40 LIGAND; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GLYCOPROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; PEPTIDES; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR BURDEN;

EID: 84905457147     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0140     Document Type: Article

References (58)

1. Gehling UM, Ergün S, Schumacher U et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95: 3106-3112
2. Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95:952-958
3. Debatin KM, Wei J, Beltinger C. Endothelial progenitor cells for cancer gene therapy. Gene Ther 2008;15:780-786
4. Dudek AZ. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. Transl Res 2010;156:136-146
5. Arap W, Pasqualini R. Engineered embryonic endothelial progenitor cells as therapeutic Trojan horses. Cancer Cell 2004;5:406-408
6. Wei J, Blum S, Unger M et al. Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 2004;5: 477-488
7. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development. Cell 2008;132:661-680
8. Li Z, Han Z, Wu JC. Transplantation of human embryonic stem cell-derived endothelial cells for vascular diseases. J Cell Biochem 2009;106:194-199
9. Park SJ, Moon SH, Lee HJ et al. A comparison of human cord blood- and embryonic stem cell-derived endothelial progenitor cells in the treatment of chronic wounds. Biomaterials 2013;34:995-1003
10. Slukvin II. Deciphering the hierarchy of angiohematopoietic progenitors from human pluripotent stem cells. Cell Cycle 2013;12: 720-727
11. White MP, Rufaihah AJ, Liu L et al. Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cellderived endothelial cells. STEM CELLS 2013;31: 92-103
12. Su W, Wang L, Zhou M et al. Human embryonic stem cell-derived endothelial cells as cellular delivery vehicles for treatment of metastatic breast cancer. Cell Transplant 2013;22: 2079-2090
13. Narsinh KH, Plews J, Wu JC. Comparison of human induced pluripotent and embryonic stem cells: Fraternal or identical twins? Mol Ther 2011;19:635-638
14. Nishikawa S, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 2008;9:725-729
15. Patel M, Yang S. Advances in reprogramming somatic cells to induced pluripotent stem cells. Stem Cell Rev 2010;6:367-380
16. Simara P, Motl JA, Kaufman DS. Pluripotent stem cells and gene therapy. Transl Res 2013;161:284-292
17. Yang J, Lam DH, Goh SS et al. Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. STEM CELLS 2012; 30:1021-1029
18. Ng ES, Davis R, Stanley EG et al. A protocol describing the use of a recombinant proteinbased, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat Protoc 2008;3: 768-776
19. James D, Nam HS, Seandel M et al. Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependent. Nat Biotechnol 2010;28:161-166
20. Zeng J, Du J, Lin J et al. High-efficiency transient transduction of human embryonic stem cell-derived neurons with baculoviral vectors. Mol Ther 2009;17:1585-1593
21. Resch T, Pircher A, Kähler CM et al. Endothelial progenitor cells: Current issues on characterization and challenging clinical applications. Stem Cell Rev 2012;8:926-939
22. Mancuso P, Calleri A, Bertolini F. Circulating endothelial cells and circulating endothelial progenitors. Recent Results Cancer Res 2012; 195:163-170
23. Ullenhag G, Loskog AS. AdCD40L-Crossing the valley of death? Int Rev Immunol 2012; 31:289-298
24. Loskog A, Tötterman TH. CD40L-A multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 2007;7: 23-28
25. Wang ZZ, Au P, Chen T et al. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol 2007;25:317-318
26. Bai H, Xie YL, Gao YX et al. The balance of positive and negative effects of TGF-b signaling regulates the development of hematopoietic and endothelial progenitors in human pluripotent stem cells. Stem Cells Dev 2013;22: 2765-2776
27. Zhang HR, Chen FL, Xu CP et al. Incorporation of endothelial progenitor cells into the neovasculature of malignant glioma xenograft. J Neurooncol 2009;93:165-174
28. Baghbaderani BA, Behie LA, Sen A et al. Expansion of human neural precursor cells in large-scale bioreactors for the treatment of neurodegenerative disorders. Biotechnol Prog 2008;24:859-870
29. Kehoe DE, Jing D, Lock LT et al. Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. Tissue Eng Part A 2010; 16:405-421
30. Niebruegge S, Bauwens CL, Peerani R et al. Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygencontrolled bioreactor. Biotechnol Bioeng 2009;102:493-507
31. Rungarunlert S, Techakumphu M, Pirity MK et al. Embryoidbody formationfrom embryonic and induced pluripotent stem cells: Benefits of bioreactors. World J Stem Cells 2009;1: 11-21
32. Lee EX, Lam DH, Wu C et al. Glioma gene therapy using induced pluripotent stem cell derived neural stem cells. Mol Pharm 2011;8: 1515-1524
33. Bak XY, Lam DH, Yang J et al. Human embryonic stem cell-derived mesenchymal stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma. Hum Gene Ther 2011;22:1365-1377
34. Zhu D, Lam DH, Purwanti YI et al. Systemic delivery of fusogenic membrane glycoprotein-expressing neural stem cells to selectively kill tumor cells. Mol Ther 2013;21: 1621-1630
35. Zhao Y, Lam DH, Yang J et al. Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors. Gene Ther 2012;19:189-200
36. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557-563
37. Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells 2010;2:5-12
38. Klopp AH, Gupta A, Spaeth E et al. Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth? STEM CELLS 2011; 29:11-19
39. Ben-Hur T. Immunomodulation by neural stem cells. J Neurol Sci 2008;265:102-104
40. Michel-Monigadon D, Brachet P, Neveu I et al. Immunoregulatory properties of neural stem cells. Immunotherapy 2011;3(suppl):39-41
41. Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev 2011;10:410-415
42. Shahbazi M, Kwang TW, Purwanti YI et al. Inhibitory effects of neural stem cells derived from human embryonic stem cells on differentiation and function of monocyte- derived dendritic cells. J Neurol Sci 2013;330:85-93
43. Dong Z, Nör JE. Transcriptional targeting of tumor endothelial cells for gene therapy. Adv Drug Deliv Rev 2009;61:542-553
44. Keung EZ, Nelson PJ, Conrad C. Concise review: Genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy. STEM CELLS 2013;31:227-235
45. Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res 2010;79:217-223
46. Haviv I, Polyak K, Qiu W et al. Origin of carcinoma associated fibroblasts. Cell Cycle 2009;8:589-595
47. Diaconu I, Cerullo V, Hirvinen MLM et al. Immune response is an important aspect of the antitumor effect produced by a CD40Lencoding oncolytic adenovirus. Cancer Res 2012;72:2327-2338
48. Gomes EM, Rodrigues MS, Phadke AP et al. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 2009;15:1317-1325
49. Fernandes MS, Gomes EM, Butcher LD et al. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res 2009;15:4847-4856
50. Biagi E, Yvon E, Dotti G et al. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther 2003;14: 545-559
51. Airenne KJ, Hu YC, Kost TA et al. Baculovirus: An insect-derived vector for diverse gene transfer applications. Mol Ther 2013;21: 739-749
52. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther 2004;11(suppl 1):S10-S17
53. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. Gene Ther 2003;10: 955-963
54. Strauss R, Hüser A, Ni S et al. Baculovirusbased vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein. Mol Ther 2007;15:193-202
55. Ramachandra CJA, Shahbazi M, Kwang TWX et al. Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors. Nucleic Acids Res 2011;39:e107
56. Phang RZ, Tay FC, Goh SL et al. Zinc finger nuclease-expressing baculoviral vectors mediate targeted genome integration of reprogramming factor genes to facilitate the generation of human induced pluripotent stem cells. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:935-945
57. Tay FC, Tan WK, Goh SL et al. Targeted transgene insertion into the AAVS1 locus driven by baculoviral vector-mediated zinc finger nuclease expression in human-induced pluripotent stem cells. J Gene Med 2013;15:384-395
58. Zhu H, Lau CH, Goh SL et al. Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. Nucleic Acids Res 2013;41:e180.